Melissa J. Moore
|UMASS Medical School, Worcester, MA, United States|
Google:"Melissa J. Moore"
Melissa J. Moore, Ph.D., CSO, mRNA Research Platform, Moderna
In her role as Chief Scientific Officer of Moderna’s mRNA research platform, Dr. Melissa Moore is responsible for leading all mRNA biology research at Moderna. She joined Moderna from the University of Massachusetts Medical School (UMMS), where she served as Professor of Biochemistry & Molecular Pharmacology, Eleanor Eustis Farrington Chair in Cancer Research and Investigator at the Howard Hughes Medical Institute (HHMI). Dr. Moore was also a founding Co-Director of the RNA Therapeutics Institute (RTI) at UMMS, and was instrumental in the creation of the Massachusetts Therapeutic and Entrepreneurship Realization initiative (MassTERi), a faculty-led program intended to facilitate the translation of UMMS discoveries into drugs, products, technologies and companies. Dr. Moore’s research at UMMS and HHMI encompassed a broad array of topics related to the role of RNA and RNA-protein (RNP) complexes in gene expression and touched on many human diseases including cancer, neurodegeneration and preeclampsia. Prior to UMMS, she spent 13 years as a professor at Brandeis University. She began working on RNA during her postdoctoral training with Phillip Sharp, Ph.D., Institute Professor, Koch Institute for Integrative Cancer Research at MIT, where she also received her Ph.D. in Biological Chemistry. Dr. Moore holds a BS in Chemistry and Biology from the College of William and Mary. Upon joining Moderna, Dr. Moore has retained her academic affiliation with UMMS as a part-time faculty member.
Cross-listing: Cell Biology Tree
ParentsSign in to add mentor
ChildrenSign in to add trainee
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
|Kovalak C, Donovan S, Bicknell AA, et al. (2021) Deep sequencing of pre-translational mRNPs reveals hidden flux through evolutionarily conserved alternative splicing nonsense-mediated decay pathways. Genome Biology. 22: 132|
|Mauger DM, Cabral BJ, Presnyak V, et al. (2019) mRNA structure regulates protein expression through changes in functional half-life. Proceedings of the National Academy of Sciences of the United States of America|
|Saini H, Bicknell AA, Eddy SR, et al. (2019) Free circular introns with an unusual branchpoint in neuronal projections. Elife. 8|
|Kucukural A, Yukselen O, Ozata DM, et al. (2019) DEBrowser: interactive differential expression analysis and visualization tool for count data. Bmc Genomics. 20: 6|
|Saini H, Bicknell AA, Eddy SR, et al. (2019) Author response: Free circular introns with an unusual branchpoint in neuronal projections Elife|
|Turanov AA, Lo A, Hassler MR, et al. (2018) RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nature Biotechnology|
|Metkar M, Ozadam H, Lajoie BR, et al. (2018) Higher-Order Organization Principles of Pre-translational mRNPs. Molecular Cell. 72: 715-726.e3|
|Didiot MC, Ferguson CM, Ly S, et al. (2018) Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin. Cell Reports. 24: 2553-2560.e5|
|Jain R, Frederick JP, Huang EY, et al. (2018) MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct. Nucleic Acid Therapeutics|
|Braun JE, Friedman LJ, Gelles J, et al. (2018) Synergistic assembly of human pre-spliceosomes across introns and exons. Elife. 7|